Trial Profile
Efficacy and Safety of Nimotuzumab in Addition to Radiotherapy and Temozolomide for Cerebral Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Biotech Pharmaceutical
- 05 Jan 2018 New trial record